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210 Importance of CF-formula in the nutrition of children with cystic
ﬁbrosis
D. Sands1, M. Mielus1, J. Pawlowicz2, R. Piotrowski1, A. Minarowska3,
A. Milanowski1. 1Pediatrics, Institute of Mother and Child, Warsaw, Poland;
2Pediatrics, Pediatric Center, Wroclaw, Poland; 3Pediatrics, Medical Academy,
Bialystok, Poland
Milupa Cystilac – cf formula – is a hypercaloric formula based on the speciﬁc
nutritional needs of children with CF (cystic ﬁbrosis) in their ﬁrst years of life.
Cystilac is higher in energy, fat, protein, vitamins, minerals and trace elements than
a formula for healthy children.
The aim of our study was to assess the effectiveness of Cystilac in nutrition for
children with CF.
33 children aged from 3 to 15 months were enrolled in this 6 month duration study.
28 children ﬁnished the observation. The remaining 5 patients withdrew prematurely
because of milk protein allergy. 28 children with CF, which were fed according to
their needs with standard formula, were the control group.
Their height, weight and head circumference were measured every 3 months. Blood
tests were performed at the beginning and at the end of the study (prealbumins,
total protein, sodium, vitamins A and E, RBC, WBC, haemoglobin). Every month
acceptance and tolerance of Cystilac were checked. After 2 and 5 months the parents
prepared detailed nutritional protocols, analyzed by dietician. Statistical analysis of
the studied children and the control group was based on the T-Student test.
There was no statistical difference in somatic development between the groups
(short period of observation).
The parameters of vitamin A, E (11.1−17.5 nmol/l), protein (61.4−64.4 g/l), prealbu-
mins (0.243−0.273 g/l) and RBC were however signiﬁcantly higher in the Cystilac
group, as were energy, protein, and carbohydrate dietary intake.
Cystilac seems to be practical, effective and convenient diet for CF children. It
appears to be well tolerated and accepted by CF infants and children.
Supported by: Nutricia Research Foundation.
211 Does an integrated clinical and nutritional approach prevent
pre-diabetic decline?
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D. Peckham. Adult CF Unit, Seacroft Hospital, Leeds, United Kingdom
Pre-diabetic clinical decline is well documented in cystic ﬁbrosis related diabetes
(CFRD). We introduced screening for CFRD incorporating annual oral glucose
tolerance testing in 1995. This is integral to an aggressive clinical and nutritional
approach.
This case control study examines the impact of clinical approach on pre and post-
CFRD clinical course. 48 CFRD patients (mean age 25.9+5.9 yrs) matched to
48 CF controls (25.9+6.3 yrs) for age, sex, Pseudomonal status had parameters of
clinical status and nutritional intervention recorded annually from 6 yrs pre CFRD
to 2 yrs post.
Weight and BMI increased throughout the study in both groups but were lower for
CFRD at all time points to diagnosis (NS). Values were stable as % of control values
[wt 96.6% (6 yr pre) v 97.5% (yr 0), BMI 98.9% (6 yr pre) v 98.0% (yr 0)]and
were above controls 2 yr post diagnosis [wt 102%, 60.3 v 59.2 kg (NS), BMI 21.5
v 21 (NS)].
Lung function declined in both groups to diagnosis [absolute FEV1 63% to 46.5%,
p = 0.0008 (CFRD), 66% to 52.6% p= 0.009 (CF)]. FEV1, FVC were below controls
(NS), deviated from 1 year pre diagnosis [FEV1 as a % of controls = 95.4% (6 yr
pre), 94.1% (1 yr pre) 86.6% (yr 0) NS], [FVC 96.2% (6 yr pre), 101.2% (1 yr pre)
93% (yr 0) NS] and stabilised on insulin therapy.
Nasogastric/gastrostomy feeding increased in both groups to diagnosis [18.8 to
43.8%, c2 = 6.9, DF = 1, p = 0.008 (CFRD)], 8.3 to 18.8%, NS (CF)] deviating
signiﬁcantly from controls from 2 yrs pre diagnosis. IV treatment intensiﬁed,
peaking at 1 yr post diagnosis 47.7 days/yr (CFRD) v 34.7 (CF) NS but there
was no difference in nebulised antibiotic use.
An aggressive clinical approach prevents nutritional decline and delays respiratory
decline until the year preceding diagnosis of CFRD.
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Introduction: Cystic Fibrosis Related Diabetes mellitus (CFRD) is an increasingly
recognized problem due to improved survival of patients with cystic ﬁbrosis. Until
now, dietary therapy has combined the conﬂicting principles of the usual dietary
management of cystic ﬁbrosis and diabetes mellitus.
Aim of the study: To investigate the need for new or adjusted recommendations
in dietary treatment of adult patients with CFRD.
Methods: First, a literature research was performed, based on papers found in the
databases Medline (from 1988 to the present), Cochrane, and PubMed, resulting
in draft recommendations. Second, in November 2006 the members of the Dutch
working group “Adult Cystic Fibrosis Specialist Dietitians” have discussed and
amended these recommendations, providing a ﬁnal guideline.
Results: Twenty three papers on detection and treatment of CFRD were found, but
no evidence-based dietary guidelines. No meta-analyses or randomised controlled
trials of dietary intervention in CFRD were found. As a consequence, recommen-
dations are based on cohort studies and current clinical practice reported in clinical
consensus guidelines. Adequate control of blood glucose appears to be no different
from “normal” diabetes; energy recommendations however are higher than normal
to maintain body weight; and saturated fats should not be restricted if body weight
is too low because long-term effects on heart disease in this group are unknown.
Conclusion: A ﬂow chart was developed to select different dietary treatments based
on body mass index and abnormal plasma glucose and lipid levels. It can be used
as a tool in the dietary treatment of the growing group of adult patients with CFRD.
213* Energy and nutrient intakes of paediatric subjects with
cystic ﬁbrosis (CF)
C. Corridon1, J.M. Caffrey1, S. O’Riordan2, H.A. Colgan2, M. Moloney1. 1School
of Biological Sciences, Dublin Institute of Technology, Kevin St., Dublin 8, Ireland;
2Dept. Nutrition/Dietetics, Our Lady’s Children’s Hospital, Crumlin, Dublin 12,
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Objectives: To estimate energy and nutrient intakes in CF paediatric subjects and
to compare these intakes to Irish Recommended Dietary Allowances (RDAs; Food
Safety Authority of Ireland (1999) and to CF dietary guidelines (Sinaasappel 2002,
Borowitz 2002, NHS, UK, 2000) for children and adolescents.
Subjects: 100 CF subjects (53 boys, 47 girls), aged 9−19 yrs, (mean = 15.5 yrs)
were recruited from a larger study being undertaken in Dublin, between Our Lady’s
Children’s Hospital, Children’s University Hospital and the National Children’s
Hospital.
Methods: Data on 3 day food records was collected coded and analysed using
WISP (Tinuvial Software, UK). One-sample t-tests were used for comparisons and
the independent-sample t-test was used to determine signiﬁcant differences between
boys and girls.
Results: There was no signiﬁcant difference in energy and nutrient intakes between
sexes. The CF recommendation of 120% for energy was achieved by 32% of the
group. The RDA for calcium was achieved by 5% while 9% achieved the dietary
vitamin D recommendation. Signiﬁcant (p< 0.01) low intakes of iron were noted
in 11−15 yr old girls. All subjects exceeded the RDA for vitamin C. Of the group
15% were receiving percutaneous endoscopic gastrostomy (PEG) feeds and 16%
were consuming oral nutritional supplements (ONS). Intake of vitamin supplements
was not assessed. A BMI of <50th percentile was evident in 69% of the group.
Conclusion: Particular emphasis should be given to the importance of energy and
nutrient intakes for all CF children and adolescents. Early nutrition intervention is
essential in promoting improved growth and lung function.
